8.53
+0.2805(+3.40%)
Currency In USD
Address
77 Sir John Rogerson’s Quay
Dublin, 2
Ireland
Phone
353 1 236 2500
Website
Sector
Healthcare
Industry
Biotechnology
Employees
163
First IPO Date
December 18, 2012
| Name | Title | Pay | Year Born |
| Dr. Gene G. Kinney Ph.D. | President, Chief Executive Officer & Director | 1.06M | 1969 |
| Mr. Michael J. Malecek | Chief Legal Officer & Company Secretary | 588,250 | 1966 |
| Dr. Wagner M. Zago Ph.D. | Chief Scientific Officer | 704,325 | 1973 |
| Ms. Carol D. Karp | Chief Regulatory Officer | 735,549 | 1953 |
| Mr. Brandon S. Smith | Chief Operating Officer | 796,006 | 1975 |
| Mr. Tran B. Nguyen M.B.A. | Chief Financial Officer & Chief Strategy Officer | 885,654 | 1974 |
| Mr. Mark C. Johnson C.F.A. | Vice President of Investor Relations | 0 | N/A |
| Ms. Karin L. Walker CPA | Chief Accounting Officer & Controller | 0 | 1963 |
| Dr. Chad J. Swanson Ph.D. | Chief Development Officer | 0 | N/A |
| Mr. David A. Ford | Chief People Officer | 0 | 1970 |
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson's disease; PRX004 that completed Phase I clinical trial for the treatment of Transthyretin amyloidosis; and PRX005, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX012 for the treatment of Alzheimer's disease; and dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. The company was founded in 2012 and is based in Dublin, Ireland.